Product
Talazoparib
Aliases
BMN673, BMN 673, BMN-673, MDV3800, MDV3800, BMN 673 (6 other aliases)
Name
TALA
Target
poly(ADP-ribose) polymerase
FDA Approved
Yes
Ema approved
Status
0
60 clinical trials
2 organizations
1 drug
3 abstracts
144 indications
1 document
Indication
Advanced CancerIndication
Metastatic CancerIndication
Breast CancerIndication
Breast NeoplasmsIndication
Advanced Solid TumorIndication
Metastatic Solid TumorIndication
Advanced MalignanciesIndication
NSCLCIndication
Ovarian CancerIndication
Bladder CancerIndication
Solid TumorsIndication
Prostate CancerIndication
Metastatic Solid TumorsIndication
GeneIndication
BRCA1Indication
CancerIndication
Pancreatic CancerIndication
Colorectal CancerIndication
Avelumab in Combination With TalazoparibIndication
Renal Cell CarcinomaIndication
FH-Deficient RCCIndication
Malignant NeoplasmIndication
Metastatic Malignant Solid NeoplasmIndication
Recurrent Malignant Solid NeoplasmIndication
Recurrent Cervical CarcinomaIndication
Endometrial CancerIndication
Triple-Negative Breast CancerIndication
Recurrent Fallopian Tube CarcinomaIndication
Recurrent Ovarian CarcinomaIndication
Recurrent Primary Peritoneal CarcinomaIndication
Vaginal CarcinomaIndication
Cervical Cancer, Stage IV, AJCC v8Indication
Fallopian Tube Cancer, Stage IV, AJCC v8Indication
Stage IV Ovarian CancerIndication
Primary Peritoneal Cancer (Stage IV)Indication
Stage IV Uterine Corpus Cancer AJCC v8Indication
Stage IV Vaginal Cancer AJCC v8Indication
Stage IVA Cervical Cancer AJCC v8Indication
Stage IV Fallopian Tube Cancer AJCC v8Indication
Stage IV Ovarian Cancer AJCC v8Indication
Stage IVA Uterine Corpus Cancer AJCC v8Indication
Stage IVA Vaginal Cancer AJCC v8Indication
Stage IVB Cervical Cancer AJCC v8Indication
Fallopian Tube CancerIndication
Ovarian Cancer Stage IVB AJCC v8Indication
Stage IVB Uterine Corpus Cancer AJCC v8Indication
Stage IVB Vaginal Cancer AJCC v8Indication
BRCA1 MutationIndication
BRCA2 mutationIndication
Fallopian tube cancerIndication
High-grade serous carcinomaIndication
Advanced Malignant NeoplasmIndication
ATM Gene MutationIndication
BRCA1 Gene MutationIndication
BRCA2Indication
Metastatic Malignant NeoplasmIndication
PALB2 Gene MutationIndication
Recurrent Malignant NeoplasmIndication
Acute Myeloid LeukemiaIndication
PheochromocytomaIndication
Malignant Solid NeoplasmIndication
ParagangliomaIndication
Gastrointestinal CancerIndication
Lung CancerIndication
lymphomaIndication
Non-HodgkinIndication
Multiple MyelomaIndication
Recurrent Acute Myeloid LeukemiaIndication
Pancreatic CarcinomaIndication
Breast Cancer, Stage IVIndication
Castration-Resistant Prostate CarcinomaIndication
Stage III Gastric CancerIndication
Stage IV Gastric CancerIndication
HER2-Positive Breast CarcinomaIndication
Breast CarcinomaIndication
Gastric CarcinomaIndication
Platinum-Sensitive Ovarian CarcinomaIndication
Stage III Ovarian Cancer AJCC v8Indication
Stage III Pancreatic CancerIndication
Prostate Cancer, Stage III AJCC v8Indication
Hormone Receptor Positive TumorIndication
Castration-resistant Prostate CancerIndication
Neuroendocrine TumorsIndication
Peritoneal CancerIndication
Recurrent Solid TumorIndication
Ewing SarcomaIndication
HepatoblastomaIndication
Recurrent Malignant Germ Cell TumorIndication
NeuroblastomaIndication
OsteosarcomaIndication
Recurrent rhabdoid tumorIndication
RhabdomyosarcomaIndication
Soft Tissue SarcomaIndication
Wilms TumorIndication
Malignant Germ Cell TumorIndication
Rhabdoid TumorIndication
Refractory Soft Tissue SarcomaIndication
advanced refractory solid tumorsIndication
Triple Negative Breast CancerIndication
Metastatic Triple Negative Breast CancerIndication
Metastatic or Unresectable MelanomaIndication
Stage IV Lung CancerIndication
Lung Cancer Stage IVA AJCC v8Indication
LeukemiaIndication
TumorIndication
NeoplasiaIndication
HER2/Neu NegativeIndication
triple-negative breast cancerIndication
Advanced or Recurrent Solid TumorsIndication
Breast NeoplasmIndication
Primary MyelofibrosisIndication
Post-polycythemia Vera MyelofibrosisIndication
Chronic Myelomonocytic LeukemiaIndication
Polycythemia VeraIndication
Essential ThrombocytosisIndication
Extensive-stage small cell lung cancerIndication
Gastroesophageal Junction AdenocarcinomaIndication
Stage IIIA Colorectal Cancer AJCC v8Indication
Colorectal Cancer, Stage IIIBIndication
Colorectal Cancer stage IV AJCC v8Indication
Stage IVA Colorectal Cancer AJCC v8Indication
Stage IVB Colorectal Cancer AJCC v8Indication
Stage IVC Colorectal Cancer AJCC v8Drug
talazoparibIndication
Gastric CancerClinical trial
A Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the DNA Polymerase Theta Inhibitor ART4215 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid TumorsStatus: Active (not recruiting), Estimated PCD: 2025-08-01
Clinical trial
Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative Metastatic Breast Cancer and Germline BRCA1/2 Mutations: An Observational Study Using Flatiron Electronic Health Record (EHR) DatabaseStatus: Completed, Estimated PCD: 2022-06-30
Clinical trial
Phase 1/2a Study of the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of RP-3500 Alone or in Combination With Talazoparib or Gemcitabine in Advanced Solid Tumors With ATR Inhibitor Sensitizing Mutations (TRESR Study)Status: Active (not recruiting), Estimated PCD: 2024-03-30
Clinical trial
Real-World Patient Characteristics, Treatment Patterns, and Clinical Outcomes Among Talazoparib-Treated Patients With HER2-Negative, Locally Advanced or Metastatic Breast Cancer and Germline BRCA1/2 Mutations: US Chart ReviewStatus: Completed, Estimated PCD: 2021-10-11
Clinical trial
A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of the DNA Polymerase Theta Inhibitor ART6043 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid TumorsStatus: Recruiting, Estimated PCD: 2026-05-14
Clinical trial
Avelumab Master Protocol: An Open-label Continuation Study for Participants Continuing From Pfizer-sponsored Avelumab Clinical Studies.Status: Active (not recruiting), Estimated PCD: 2026-09-30
Clinical trial
TALAPRO-1: A PHASE 2, OPEN-LABEL, RESPONSE RATE STUDY OF TALAZOPARIB IN MEN WITH DNA REPAIR DEFECTS AND METASTATIC CASTRATION-RESISTANT PROSTATE CANCER WHO PREVIOUSLY RECEIVED TAXANE-BASED CHEMOTHERAPY AND PROGRESSED ON AT LEAST 1 NOVEL HORMONAL AGENT (ENZALUTAMIDE AND/OR ABIRATERONE ACETATE/PREDNISONE)Status: Completed, Estimated PCD: 2020-09-04
Clinical trial
A PHASE 2 STUDY TO EVALUATE SAFETY AND ANTI-TUMOR ACTIVITY OF AVELUMAB IN COMBINATION WITH TALAZOPARIB IN PATIENTS WITH BRCA OR ATM MUTANT TUMORS JAVELIN BRCA/ATMStatus: Terminated, Estimated PCD: 2022-03-28
Clinical trial
A PHASE 1, OPEN LABEL, CROSSOVER STUDY TO ESTABLISH BIOEQUIVALENCE BETWEEN THE PROPOSED SOFT GEL TALAZOPARIB CAPSULE FORMULATION AND THE CURRENT TALAZOPARIB COMMERCIAL FORMULATION AND TO ESTIMATE THE FOOD EFFECT ON PHARMACOKINETICS OF THE PROPOSED TALAZOPARIB SOFT GEL CAPSULE FORMULATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORSStatus: Completed, Estimated PCD: 2022-02-04
Clinical trial
A RANDOMIZED, OPEN-LABEL, MULTICENTER, PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF AVELUMAB IN COMBINATION WITH CHEMOTHERAPY FOLLOWED BY MAINTENANCE THERAPY OF AVELUMAB IN COMBINATION WITH THE POLY (ADENOSINE DIPHOSPHATE [ADP]-RIBOSE) POLYMERASE (PARP) INHIBITOR TALAZOPARIB IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED OVARIAN CANCER (JAVELIN OVARIAN PARP100)Status: Terminated, Estimated PCD: 2021-12-22
Clinical trial
A PHASE 1B/2 STUDY TO EVALUATE SAFETY AND ANTI TUMOR ACTIVITY OF AVELUMAB IN COMBINATION WITH THE POLY(ADENOSINE DIPHOSPHATE [ADP]-RIBOSE) POLYMERASE (PARP) INHIBITOR TALAZOPARIB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC SOLID TUMORSStatus: Terminated, Estimated PCD: 2022-02-22
Abstract
TALAPRO-2: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) versus placebo (PBO) + ENZA as first-line (1L) treatment for patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) harboring homologous recombination repair (HRR) gene alterations.Org: University of Paris-Saclay, Peter MacCallum Cancer Centre, Melbourne, Australia, National Cancer Center Hospital East, Kashiwa, Japan, Vall d’Hebron University Hospital/VHIO, Barcelona, Spain,
Clinical trial
Talazoparib and Avelumab in Genomically Defined Metastatic Renal Cell CarcinomaStatus: Completed, Estimated PCD: 2023-12-06
Clinical trial
Phase 1b/2 Study to Evaluate Antibody-Drug Conjugate Sacituzumab Govitecan in Combination With PARP Inhibitor Talazoparib in Patients With Metastatic Breast CancerStatus: Recruiting, Estimated PCD: 2025-12-01
Clinical trial
Modular Phase 1B Hypothesis-Testing, Biomarker-Driven, Talazoparib Combination Trial (TalaCom)Status: Recruiting, Estimated PCD: 2025-09-03
Clinical trial
Phase II Study of Talazoparib With Androgen Deprivation Therapy and Abiraterone in Castration Sensitive Prostate CancerStatus: Recruiting, Estimated PCD: 2027-08-23
Clinical trial
Phase I Study of Talazoparib in Combination With Radiation Therapy for Locally Recurrent Gynecologic CancersStatus: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Phase II Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual Triple Negative Breast Cancer (PERSEVERE)Status: Recruiting, Estimated PCD: 2029-01-31
Clinical trial
Phase 1 Trial of Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate CancerStatus: , Estimated PCD: 2024-07-12
Clinical trial
BrUOG 390: Neoadjuvant Treatment With Talazoparib for Women With Newly Diagnosed, Advanced Ovarian Cancer Associated With a Mutation in BRCA1 or BRCA2 (mBRCA)Status: Terminated, Estimated PCD: 2022-11-30
Clinical trial
Phase II Study of the PARP Inhibitor Talazoparib in Advanced Cancer Patients With Somatic Alterations in BRCA1/2, Mutations/Deletions in Other BRCA Pathway Genes and Germline Mutation in BRCA1/2 (Not Breast or Ovarian Cancer)Status: Active (not recruiting), Estimated PCD: 2025-12-31
Clinical trial
Natural Killer Cell Immunotherapy in Combination With PARP-inhibition to Overcome NKG2D Mediated Immune Evasion in Acute Myeloid LeukemiaStatus: Not yet recruiting, Estimated PCD: 2028-06-01
Clinical trial
Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 2 Talazoparib and TemozolomideStatus: Recruiting, Estimated PCD: 2026-04-15
Clinical trial
A Phase 1 Dose-Escalation Trial of Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian CancerStatus: Recruiting, Estimated PCD: 2024-07-01
Clinical trial
The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Targeted Agent and Profiling Utilization Registry (TAPUR) StudyStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
Phase 1/1b Trial of Talazoparib and Gemtuzumab Ozogamicin in Adult Patients With Relapsed and/or Refractory Acute Myeloid LeukemiaStatus: Active (not recruiting), Estimated PCD: 2025-04-01
Clinical trial
A Randomized Phase II Trial to Evaluate the Antitumor Activity of Enzalutamide and Talazoparib (PF-06944076) for the Treatment of Metastatic Hormone-naïve Prostate CancerStatus: Active (not recruiting), Estimated PCD: 2025-04-30
Clinical trial
Phase 2 Trial With Safety Run-In of Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers Big Ten Cancer Research Consortium BTCRC-BRE18-337Status: Active (not recruiting), Estimated PCD: 2024-07-01
Clinical trial
A Pharmacodynamics-Driven Trial of Talazoparib, an Oral PARP Inhibitor, in Patients With Advanced Solid Tumors and Aberrations in Genes Involved in DNA Damage ResponseStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
FUnctional Selection of Advanced Breast Cancer Patients for Talazoparib Treatment Using the REpair Capacity (RECAP) Test: The FUTURE TrialStatus: Recruiting, Estimated PCD: 2024-12-01
Clinical trial
A Phase 2, Two-Group, Two-Stage, Open-Label Study of Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer, Avelumab / Talazoparib in Patients With MSS Recurrent or Persistent Endometrial Cancer, and Avelumab / Axitinib in Patients With MSS Recurrent or Persistent Endometrial CancerStatus: Active (not recruiting), Estimated PCD: 2025-03-01
Clinical trial
A Phase I Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/ Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast CancerStatus: Completed, Estimated PCD: 2024-01-30
Clinical trial
A Phase Ib/II Study of Intermittent Talazoparib Plus Temozolomide in Patients With Metastatic Castration Resistant Prostate Cancer and No Mutations in DNA Damage RepairStatus: Active (not recruiting), Estimated PCD: 2027-07-01
Clinical trial
Phase 2 Trial of the Combination of the BET Inhibitor, ZEN003694 (ZEN-3694), and the PARP Inhibitor Talazoparib, in Patients With Molecularly-Selected Solid Tumors (ComBET)Status: Recruiting, Estimated PCD: 2025-08-04
Clinical trial
A Multi-institutional Phase II Study to Evaluate Efficacy and Safety of TAlazoparib, Radiotherapy and Atezolizumab in gBRCA 1/2 Negative Patients With PD-L1+ Metastatic Triple Negative Breast CancerStatus: Terminated, Estimated PCD: 2022-02-18
Clinical trial
A Phase IB/II Multi-Cohort Study of Targeted Agents and/or Immunotherapy With Atezolizumab for Patients With Recurrent or Persistent Endometrial CancerStatus: Recruiting, Estimated PCD: 2025-10-01
Clinical trial
A Phase 2 Study of Continuous Talazoparib Plus Intermittent Low-Dose Temozolomide in Patients With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer (TRIO-US L-07)Status: Recruiting, Estimated PCD: 2024-10-01
Clinical trial
A Phase 2b Study of ZEN003694 in Combination With Talazoparib in Patients With Triple-Negative Breast CancerStatus: Terminated, Estimated PCD: 2024-03-07
Clinical trial
Phase 1 Trial of PARP Inhibitor Combined With 177Lu-DOTA-Octreotate Peptide Receptor Radionuclide Therapy (PRRT) in Patients With Metastatic NeuroEndocrine TumorStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Presurgical Phase II Study of Talazoparib in Combination With Enzalutamide in de Novo Metastatic to Lymph Nodes Prostate CancerStatus: Not yet recruiting, Estimated PCD: 2026-12-31
Clinical trial
Phase ll Study of a BET Inhibitor, ZEN003694, Combined With a PARP Inhibitor, Talazoparib, in Patients With Recurrent Ovarian CancerStatus: Recruiting, Estimated PCD: 2029-12-01
Clinical trial
A Phase 1 Study of Talazoparib (BMN 673) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Solid TumorsStatus: Completed, Estimated PCD: 2019-04-01
Clinical trial
A Randomized Phase I/II Study of Talazoparib or Temozolomide in Combination With Onivyde in Children With Recurrent Solid Malignancies and Ewing SarcomaStatus: Recruiting, Estimated PCD: 2025-12-31
Clinical trial
Phase I Dose Finding Study of Selinexor and Talazoparib in Patients With Advanced Refractory Solid Tumors, Followed by Phase II Expansion Cohort Study in Patients With Advanced/ Metastatic Triple Negative Breast Cancers. (START)Status: Recruiting, Estimated PCD: 2024-11-01
Clinical trial
A Phase Ia/Ib Study of Talazoparib in Combination With Tazemetostat in Metastatic Castration-resistant Prostate Cancer (mCRPC)Status: Active (not recruiting), Estimated PCD: 2025-03-30
Clinical trial
Phase II Trial of Nivolumab in Combination With Talazoparib in Patients With Unresectable or Metastatic Melanoma and Mutations in BRCA or BRCA-ness GenesStatus: Completed, Estimated PCD: 2023-10-13
Clinical trial
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCERStatus: Active (not recruiting), Estimated PCD: 2022-10-03
Clinical trial
A Phase I Protocol for Relapsed Pediatric AML to Determine the Safety and Efficacy of the PARP Inhibitor Talazoparib in Combination With ChemotherapyStatus: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
A Phase II Study of Talazoparib Plus Avelumab in Patients With Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer Bearing Pathogenic STK11 Genomic Alterations (LUNG-MAP Sub-Study)Status: Active (not recruiting), Estimated PCD: 2021-11-24
Clinical trial
A Pilot Proof-of-Concept Study of Talazoparib-Based Therapy for Cohesin-Mutated AML and MDS With Excess BlastsStatus: Recruiting, Estimated PCD: 2024-12-31
Clinical trial
A Phase 2 Clinical Trial of Talazoparib Monotherapy for PALB2 Mutation Associated Advanced Breast CancerStatus: Recruiting, Estimated PCD: 2024-03-01
Clinical trial
A Dutch National Study on Behalf of the CPCT to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to Determine the Potential Efficacy in Treatment of Advanced Cancers With a Known Molecular ProfileStatus: Recruiting, Estimated PCD: 2027-09-01
Clinical trial
Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot StudyStatus: Terminated, Estimated PCD: 2022-12-30
Clinical trial
Study to Investigate Outcome of Individualized Treatment Based on Pharmacogenomic Profiling & Ex Vivo Drug Sensitivity Testing of Patient-derived Organoids in Patients With Metastatic Colorectal CancerStatus: Recruiting, Estimated PCD: 2038-12-31
Clinical trial
A Phase II Clinical Trial of the PARP Inhibitor Talazoparib in BRCA1 and BRCA2 Wild Type Patients With Advanced Triple Negative Breast Cancer and Homologous Recombination Deficiency or Advanced HER2 Negative Breast Cancer or Other Solid Tumors With a Mutation in Homologous Recombination Pathway GenesStatus: Completed, Estimated PCD: 2019-12-23
Clinical trial
Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Advanced Solid Tumors ( Phase I )Status: Withdrawn, Estimated PCD: 2023-12-10
Clinical trial
Phase I Study Accessing the Safety of Pacritinib in Combination With Talazoparib in Patients With Myeloproliferative Neoplasms Unresponsive to Frontline JAK2 (Janus Kinase 2) InhibitionStatus: Recruiting, Estimated PCD: 2029-08-22
Clinical trial
Phase II Randomized Study of Maintenance Atezolizumab Versus Atezolizumab in Combination With Talazoparib in Patients With SLFN11 Positive Extensive Stage Small Cell Lung Cancer (ES-SCLC)Status: Active (not recruiting), Estimated PCD: 2025-11-30
Clinical trial
A Phase I Study of Trifluridine/ Tipiracil Plus the Poly (ADP) Ribose Polymerase Inhibitor Talazoparib in Advanced CancersStatus: Recruiting, Estimated PCD: 2024-07-01
Document
DailyMed Label: TalzennaOrganization
Pfizer Laboratories Div Pfizer IncOrganization
U.S. Pharmaceuticals